High Prevalence of Anti-Apolipoprotein/A-1 Autoantibodies in Maintenance Hemodialysis and Association With Dialysis Vintage

Therapeutic Apheresis and Dialysis

Volumn 16, Issue 6, 2012, Pages 588-594

  Pruijm, Menno ^a   Schmidtko, Jan ^a   Aho, Anthony ^a   Pagano, Sabrina ^b   Roux Lombard, Pascale ^b   Teta, Daniel ^a   Burnier, Michel ^a   Vuilleumier, Nicolas ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Apolipoprotein A 1; Atherosclerosis; Autoantibodies; Cardiovascular risk; Inflammation; Maintenance hemodialysis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGED; ANTIBODY TITER; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIALYSIS VINTAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLAQUE, ATHEROSCLEROTIC; PREVALENCE; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS;

EID: 84870490313     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01102.x     Document Type: Article

References (31)

1. Anavekar NS, McMurray JJ, Velazquez EJ etal. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95.
2. Nolan CR. Strategies for improving long-term survival in patients with ESRD. J Am Soc Nephrol 2005;16(Suppl 2):S120-S127.
3. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008;3:505-21.
4. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008;54:24-38.
5. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-58.
6. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684-8.
7. Pawlak K, Pawlak D, Mysliwiec M. Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease. Am J Nephrol 2004;24:635-40.
8. Kato S, Chmielewski M, Honda H etal. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008;3:1526-33.
9. Carrero JJ, Hua X, Stenvinkel P etal. Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. Nephrol Dial Transplant 2009;24:3454-60.
10. Pawlak K, Pawlak D, Mysliwiec M. Oxidative stress influences CC-chemokine levels in hemodialyzed patients. Nephron Physiol 2004;96:105-12.
11. Pawlak K, Pawlak D, Mysliwiec M. Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 2007;190:199-204.
12. Vuilleumier N, Charbonney E, Fontao L etal. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci (Lond) 2008;115:25-33.
13. Vuilleumier N, Reber G, James R etal. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 2004;23:353-60.
14. Vuilleumier N, Rossier MF, Pagano S etal. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 2010;31:815-23.
15. Ohtake T, Ishioka K, Honda K etal. Impact of coronary artery calcification in hemodialysis patients: risk factors and associations with prognosis. Hemodial Int 2010;14:218-25.
16. Wilson WA, Gharavi AE, Koike T etal. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
17. Vuilleumier N, Bas S, Pagano S etal. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2010;62:2640-50.
18. Montecucco F, Vuilleumier N, Pagano S etal. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011;32:412-21.
19. Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafstrom I, Frostegard J. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scand J Rheumatol 2010;39:447-53.
20. Batuca JR, Ames PR, Amaral M, Favas C, Isenberg DA, Delgado AJ. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:26-31.
21. Montecucco F, Bertolotto M, Vuilleumier N etal. Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. Am J Physiol Endocrinol Metab 2011;300:E681-E690.
22. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997;12:2603-11.
23. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006;37:1923-32.
24. Van Lenten BJ, Hama SY, de Beer FC etal. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-67.
25. Cengiz N, Baskin E, Sezgin N, Agras P, Haberal M. Oxidative stress in children on hemodialysis: value of autoantibodies against oxidized low-density lipoprotein. Pediatr Nephrol 2009;24:387-93.
26. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-76.
27. Finckh A, Courvoisier DS, Pagano S etal. Evaluation of cardiovascular risk in patients with rheumatoid arthritis. Do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? Arthritis Care Res 2012;64:817-25.
28. Pagano S, Satta N, Werling D etal. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex. J Intern Med 2012; doi: 10.1111/j.1365-2796.2012.02530.x [Epub ahead of print].
29. Kalantar-Zadeh K, Balakrishnan VS. The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodial Int 2006;10:315-25.
30. Kaysen GA, Dubin JA, Muller HG, Rosales L, Levin NW, Mitch WE. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 2004;65:1408-15.
31. Roux-Lombard P, Pagano S, Montecucco F, Satta N, Vuilleumier N. Auto-antibodies as Emergent Prognostic Markers and Possible Mediators of Ischemic Cardiovascular Diseases. Clin Rev Allergy Immunol 2010; epub ahead of print.